Dioxydine

Summary

Dioxydine (CHEMBL5314960) is a phase-3 clinical-stage small molecule; indicated across 2 conditions including pyoderma.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Indications: 2 conditions
• Clinical trials: 3
• Chemistry: 222.2 Da · C10H10N2O4

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL5314960
Name	Dioxydine
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	28467
Molecular formula	C10H10N2O4
Molecular weight	222.2
InChIKey	DOIGHQCAQBRSKI-UHFFFAOYSA-N

SMILES: C1=CC=C2C(=C1)N(C(=C([N+]2=O)CO)CO)[O-]

IUPAC name: [3-(hydroxymethyl)-1-oxido-4-oxoquinoxalin-4-ium-2-yl]methanol

Also known as: Chinoxalindimethanol dioxide, Dioxidin, Dioxidine, Dioxydine, Hydroxymethylquinoxalindioxyde, Metrosept, DIOXYDINE

Patent coverage: 45 distinct patent families (47 SureChEMBL compound mentions), from 3 matched compound structure(s). One matched structure accounts for 39 (83%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
pyoderma	3	MONDO:0002922	HP:0000999

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 3.

Phase distribution

Phase	Trials
PHASE3	1
PHASE1	1
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT05561816	PHASE3	COMPLETED	Efficacy and Safety of Dioxidin Versus Miramistin in Superficial Pyoderma
NCT05505097	PHASE1	COMPLETED	Safety and Pharmacokinetics of Dioxidin, Solution for Topical and External Use, 0.25 mg/ml and Dioxidin, Solution for Infusion and External Use, 5 mg/ml in Healthy Volunteers
NCT07393711	Not specified	NOT_YET_RECRUITING	Metaphylaxis of Infected Kidney Stones After Percutaneous Nephrolithotripsy

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).